Netupitant/palonosetron
Pharmaceutical drug
From Wikipedia, the free encyclopedia
Netupitant/palonosetron, sold under the brand name Akynzeo, is a fixed-dose combination medication used for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.[7][9] It is marketed and distributed by Helsinn Therapeutics. Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist.[10]
| Combination of | |
|---|---|
| Netupitant | NK1 receptor antagonist |
| Palonosetron | 5-HT3 receptor antagonist |
| Clinical data | |
| Trade names | Akynzeo |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614053 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth, intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
The capsules contain netupitant and palonosetron hydrochloride. The intravenous version is a combination of fosnetupitant chloride hydrochloride and palonosetron hydrochloride.[11][7][8]
Contraindications
Adverse effects
The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness.[7] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[12]
Interactions
Pharmacology
History
Netupitant/palonosetron was approved for use in the United States in October 2014.[14] It was approved for use in the European Union in May 2015.[8] The intravenous version, which contains the prodrug fosnetupitant in place of netupitant, was approved in the United States in April 2018.[15][11]
